MacroGenics, Inc. Announces Presentation Of Pre-Clinical Data On DART® Molecule Targeting CD123-Positive Leukemic Stem Cells At 55th Annual Meeting Of The American Society of Hematology

Published: Dec 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., Dec. 9, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data for its proprietary DART® molecule, MGD006, at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans. These data demonstrate activity of MGD006, a bispecific molecule that redirects T cells against CD123-positive leukemic cells and results in the clearance of acute myeloid leukemia (AML) blasts in vitro and in vivo.

Help employers find you! Check out all the jobs and post your resume.

Back to news